Advances in Brain Tumor Therapy

Arun Kumar Singh is Assistant Professor in the Department of Pharmacy at the University School of Pharmaceutical Sciences, Rayat Bahra University, Sahauran, India. His research interests include nano-formulation, cancer biology, and neuroscience, alongside digital and computational approaches such as machine learning, artificial intelligence, big data analytics, blockchain, and the Internet of Things. He has contributed academic books, book chapters, and review articles in pharmaceutical sciences and healthcare technology, with a focus on interdisciplinary approaches that integrate pharmaceutical research with emerging digital technologies.

Dr. Thakur Gurjeet Singh is a pharmacology researcher with extensive graduate training in clinical and preclinical drug development. His work focuses on the neuroprotective mechanisms of pharmacological preconditioning in neurodegenerative disorders such as Alzheimer’s disease, Parkinsonism, stroke, epilepsy, and dementia. He has investigated key protective pathways involving adenosine, opioids, CGRP, calcium signaling, protein kinase-C, heat shock proteins, and MAP kinase. His research also explores novel therapeutic pathways using agents such as morphine and capsaicin, with additional expertise in mechanistic studies of substance dependence, including nicotine, alcohol, and morphine addiction. Dr. Singh’s core competencies include animal model development and validation, anesthetic and preconditioning techniques, histopathological analysis, and behavioral data evaluation. His broader interests include ALS, stem cell therapy, and movement disorders such as tardive dyskinesia.

Dr. Niraj Kumar Jha is an Assistant Professor of Biotechnology at Galgotias University, India, with prior research affiliations at the Centre for Research Impact & Outcome (CRIO), Chitkara University, and Sharda University. His research portfolio encompasses over 200 peer-reviewed articles and scholarly reviews, along with an edited volume published by Springer, reflecting sustained contributions to biomedical research and translational science. According to Scopus metrics, Dr. Jha’s publications have garnered more than 10,000 citations, with an H-index exceeding 50, underscoring the broad impact and visibility of his work within the global scientific community. He is an elected Member of the Royal Society of Biology (MRSB), London, and has been recognized among the World’s Top 2% Scientists in rankings compiled by Elsevier in collaboration with Stanford University. Dr. Jha actively contributes to scientific publishing and peer review as an associate editor for the Journal of Alzheimer’s Disease (IOS Press) and IET Nanobiotechnology (Wiley) and serves on the editorial boards of several international journals, including Scientific Reports. His research is centered on elucidating the molecular and cellular mechanisms underlying complex diseases such as neurodegenerative disorders, cancer, and cardiovascular pathologies. His work particularly emphasizes the modulation of key signaling pathways and explores the therapeutic potential of natural products, phytochemicals, and synthetic small molecules in disease intervention.